1. Home
  2. VKTX

VKTX

Viking Therapeutics Inc.

Logo Viking Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 8.4B IPO Year: 2015
Target Price: $95.40 AVG Volume (30 days): 6.5M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.91 EPS Growth: N/A
52 Week Low/High: $8.28 - $99.41 Next Earning Date: 04-29-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: